Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?

• Published in: Arthritis Care & Research
• Main Authors: Almeida‐Brasil, Celline C., Pineau, Christian A., Vinet, Evelyne, Hanly, John G., Peschken, Christine A., Clarke, Ann E., Fortin, Paul R., Abrahamowicz, Michal, Bernatsky, Sasha
• Other Authors: Canadian Institutes of Health Research, Fonds de Recherche du Québec-Société et Culture, McGill University Health Centre, Lupus Canada
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2022
• Subjects: First Nations
• Online Access: http://dx.doi.org/10.1002/acr.24548; https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.24548; https://onlinelibrary.wiley.com/doi/full-xml/10.1002/acr.24548

Objective Hydroxychloroquine (HCQ) is a key systemic lupus erythematosus (SLE) drug, making concerns of drug shortages grave. Our objective was to evaluate factors associated with poor outcomes after HCQ taper or discontinuation in SLE. Methods We studied 5 Canadian SLE cohorts between 1999 and 2019, following patients from the date of HCQ tapering (cohort 1) or discontinuation (cohort 2). A composite outcome was defined as any of the following: a need for therapy augmentation, an increase (of at least 4 points) in the Systemic Lupus Erythematosus Disease Activity Index 2000 score, or hospitalization for SLE. In each cohort, multivariable Cox regression was used to identify demographic and clinical factors associated with time to the earliest of these events. A third cohort continuing to receive HCQ was also studied, to assess whether the same factors influenced the outcome even when the HCQ dose was unchanged. Results The poor outcome rate, per 100 person‐years, was 35.7 (95% confidence interval [95% CI] 31.6–40.3) in the HCQ taper cohort (n = 398), 29.0 (95% CI 25.5–33.0) in the discontinuation cohort (n = 395), and 16.1 (95% CI 13.2–19.6) in the maintenance cohort (n = 395). In patients tapering HCQ, baseline prednisone use was independently associated with greater risk of poor outcomes. In the discontinuation cohort, the risk of poor outcomes was greater for Black patients and those diagnosed with SLE at age ≤25 years. Among those maintaining HCQ, baseline immunosuppressive use and First Nations ethnicity were associated with poor outcomes. Conclusion We identified demographic and clinical factors associated with poor outcomes after HCQ taper/discontinuation. This information is critical in the current setting of potential shortages, but over the long term, such information could inform personalized therapies.